期刊
NATURE REVIEWS IMMUNOLOGY
卷 15, 期 4, 页码 255-263出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nri3813
关键词
-
类别
资金
- Division of AIDS, NIAID, US National Institutes of Health, Department of Health and Human Services [HHSN272201200009C]
Improved treatments are needed for nearly all forms of Mycobacterium tuberculosis infection. Adjunctive host-directed therapies have the potential to shorten tuberculosis treatment duration, prevent resistance and reduce lung injury by promoting autophagy, antimicrobial peptide production and other macrophage effector mechanisms, as well as by modifying specific mechanisms that cause lung inflammation and matrix destruction. The range of candidates is broad, including several agents approved for other clinical indications that are ready for evaluation in Phase II clinical trials. The promise of new and existing host-directed therapies that could accelerate response and improve tuberculosis treatment outcomes is discussed in this Opinion article.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据